KPI data tables
Emergent BioSolutions operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | USG MCM | Non-USG MCM |
|---|---|---|
| FY 2025 | 300.2 | 156.5 |
| FY 2024 | 381.3 | 128.5 |
| FY 2023 | 373.5 | 73.7 |
Source: Emergent Form 10-K for the year ended December 31, 2025, Note 14 Revenue recognition, MCM Product sales USG / Non-USG / Total (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm): FY 2025 $300.2 / $156.5 / $456.7 million. FY 2024 $381.3 / $128.5 / $509.8 million. FY 2023 $373.5 / $73.7 / $447.2 million. FY 2025 international MCM share of 34% of MCM revenue: Q4 2025 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs2025-12x31deck.htm). H1 2026 international MCM 20% of H1 MCM revenues: Q2 2026 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/ebs2026-06x30deckfinal.htm).
| Period | NARCAN doses (millions) |
|---|---|
| FY 2024 | 22 |
| FY 2023 | 22 |
Source: Emergent Q4 2023 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764424000026/ebs2023-12x31deckfinalmi.htm): in 2023, distributed about 22 million doses / about 11 million two-dose boxes in the US and Canada. Q4 2024 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/ebs2024-12x31deck.htm): in 2024, distributed about 11 million cartons / 22 million doses, consistent with 2023. FY 2025 annual report letter (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000035/ebsi_2025annualreport.htm): distributed over 100 million doses of NARCAN Nasal Spray across the US and Canada since 2016 (cumulative floor, not an annual print).
| Period | Naloxone (NARCAN / KLOXXADO) | Anthrax MCM | Smallpox MCM | Other Products (BAT / RSDL) |
|---|---|---|---|---|
| Q3 2026 | 43.5 | 25.1 | 26.7 | 7.6 |
| Q2 2026 | 52.4 | 12.3 | 101.6 | 54.1 |
| Q1 2026 | 42.9 | 21.6 | 64.2 | 16 |
| Q4 2025 | 38.4 | 53.4 | 35.5 | 10.3 |
| Q3 2025 | 74.9 | 1.4 | 83.6 | 57.5 |
| Q2 2025 | 67.5 | 11.6 | 40.6 | 6.2 |
| Q1 2025 | 45.3 | 47.9 | 106.4 | 2.3 |
| Q4 2024 | 65.1 | 32.5 | 76.5 | 7.8 |
| Q3 2024 | 95.3 | 11.4 | 132.7 | 30.1 |
| Q2 2024 | 120 | 38.7 | 17.9 | 6.8 |
| Q1 2024 | 118.5 | 55.9 | 50.2 | 49.3 |
Source: Emergent BioSolutions product sales, net tables in quarterly earnings releases and Form 10-Q/10-K MD&A. Q1 2024: https://www.globenewswire.com/news-release/2024/05/01/2873704/33240/en/Emergent-BioSolutions-Reports-First-Quarter-2024-Financial-Results.html (NARCAN 118.5, Anthrax 55.9, Smallpox 50.2, Other 49.3). Q2 2024: https://investors.emergentbiosolutions.com/node/23031/pdf (120.0 / 38.7 / 17.9 / 6.8). Q3 2025 release reprints Q3 2024: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/ebs2025-09x30ex99er.htm (95.3 / 11.4 / 132.7 / 30.1). Q4 2025 release reprints Q4 2024: https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-reports-fourth-quarter-and-full-year-2025 (65.1 / 32.5 / 76.5 / 7.8). FY 2025 10-K annuals (226.1 / 114.3 / 266.1 / 76.3) at https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm. Q1 to Q4 2025 from the Q4 2025, Q3 2025, and Q2 2026 comparisons. Q1 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/ebs20260331ex99er.htm (42.9 / 21.6 / 64.2 / 16.0). Q2 2026 Form 10-Q: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/ebs-20260630.htm (52.4 / 12.3 / 101.6 / 54.1). Q3 2026 Form 8-K Exhibit 99.1: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000110/ebs202609-30ex99er.htm (43.5 / 25.1 / 26.7 / 7.6).
| Period | Total RPO | Expected within 24 months |
|---|---|---|
| Q3 2026 | 241.9 | 222.7 |
| Q2 2026 | 268.7 | 247.7 |
| Q1 2026 | 248 | 210.4 |
| Q4 2025 | 244.4 | 203.8 |
| Q3 2025 | 322.5 | 259.2 |
| Q2 2025 | 296.9 | 227.5 |
| Q1 2025 | 270.4 | 199.3 |
| Q4 2024 | 393.2 | 348.2 |
Source: Emergent Form 10-K and Form 10-Q, Revenue recognition note, Transaction price allocated to remaining performance obligations. YE 2024: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm ($393.2 million total, $348.2 million within 24 months). Q1 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000124/ebs-20250331.htm ($270.4 / $199.3). Q2 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000181/ebs-20250630.htm ($296.9 / $227.5). Q3 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000202/ebs-20250930.htm ($322.5 / $259.2). YE 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm ($244.4 / $203.8). Q1 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000065/ebs-20260331.htm ($248.0 / $210.4). Q2 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/ebs-20260630.htm ($268.7 / $247.7). Q3 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000112/ebs-20260930.htm ($241.9 / $222.7).
| Period | US government | Non-USG customers |
|---|---|---|
| FY 2025 | 339.7 | 403.2 |
| FY 2024 | 410.5 | 633.1 |
| FY 2023 | 394.7 | 654.6 |
Source: Emergent Form 10-K for the year ended December 31, 2025, Note 14 Revenue recognition, revenues disaggregated by major sources (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm). FY 2025: USG $339.7 million, Non-USG $403.2 million, total $742.9 million. FY 2024: $410.5 / $633.1 / $1,043.6 million. FY 2023: $394.7 / $654.6 / $1,049.3 million. Same note: no non-USG customer above 10% of total revenues in those years. US geographic share 71% / 79% / 58% for 2025 / 2024 / 2023 is printed separately and is not this series.